Avacta #AVCT just doing another lap of the ground after another home run!
ATRI warhead confirmed as Berzosertip - Owned by MERCK KGaA!!
'AVA6207 overcomes Top1 resistance'!
'Avacta is the first company to develop a PDC capable of delivering two payloads directly to the tumor via a single, tumor-specific cleavage event.'
Complete responses aka cures in preclinical setting.
This is very pioneering moves being made here. This is not a drill. Well done to the incredible team again.
With no dual payloads approved at all by the FDA to date and AVCT being the likely first ever PDC dual payload to go into IND enabling studies (shortly) and achieve complete responses already is quite something. When they have stated numerous times that for both their AVA6000 and AVA6103 programmes the translation from preclinical to humans has only got better this is an excellent starting point. Big change is coming.
https://t.co/jf3YGWjdUW
It feels like late 2019 / early 2020 all over again for @avacta#AVCT. I believe the share price sits on the cusp of a monumental breakout.
To fully appreciate the extraordinary asymmetric opportunity here, investors need to work through four sequential topics.
1) The science. A best-in-class delivery platform for treating the large majority of all cancer cases. It takes time to get one’s head around the sheer scale of what Avacta has already achieved with pre|CISION, and how the platform vastly outperforms the various competing technologies and modalities in targeted oncology, in a plethora of ways.
2) Potential value. If you have gotten to grips with 1) above, you will be able to appreciate that there’s a genuine possibility of Avacta’s first Gen2 and Gen3 assets - AVA6103 and AVA6207 - becoming all-time best-selling oncology drugs – and consequently, of Avacta surpassing the leading targeted oncology companies / acquisitions (Revolution, Seagen, etc.) in value over the next 2-3 years.
3) Understanding why a chronic undervaluation has persisted. There are three key matters to consider here: i) the LSE is a shadow of its former self, the UK investment community struggling. ii) the Avacta retail base has been subject to intense share price volatility and consequently suffers from a severe case of PTSD. iii) the development of the pre|CISION platform by a hitherto little-known AIM-listed company appears to be a too-good-to-be-true story, for those who have not looked closely.
4) Understanding why this undervaluation is unlikely to last much longer. Next month, we’ll see the first biopsy data for AVA6103. In the first few months of next year, we’ll start to receive efficacy data from the trial. These are critical landmarks for the company: it will open the market’s eyes to the gulf in ability (and value) between Avacta’s Gen1 platform and Gen2 platform. A partnership for AVA6000 (free carry from end P1b through to sales, ideally) would also be a major boost, as would a platform out-licensing deal that could bring in a sizeable cash injection. Finally, a dual NASDAQ listing (hopefully to be announced in the next several months) would (in my view) also be very well received by the market, to combat 3) i) above.
I intend to post detailed notes on each of the above four topics, shortly. I envy (intensely!) those who can today buy a big chunk of AVCT for the very first time, at 57p. The platform has been enormously derisked the past six months, yet the share price has reacted negatively in that timeframe. I simply cannot see this status quo lasting much longer. The upside in the relatively near-term is just too vast, relative to the current mkt cap.
Unappreciated aspect of AVA6103’s speed.
Suspect we see efficacy early Q1 and P1b early Q2.
The trial design enables AVCT to backfill P1a as it awaits the FDA’s approval for P1b commencement. This will be at the dose one below the current level.
#AVCT
We only have to convince BP on our terms at this point the flock of sheep then follows. I take your point but I'm not worried about those specialists when BP are the difference here. The science is so good it is not if but just when.
Most understand the purpose and context of 6k and the drastic step change in capability TX I, half-life, linker etc etc vs gen 2 (AVA6103) and 3 (AVA6207) assets is night and day which is why 6k is not a concern anymore. They deal on it for sure and people will be surprised when they do.
In 2 days #AVCT present AVA6207 its Next Generation pre|CISION dual payload PDC (peptide drug conjugate) at EORTC-NCI-AACR. This is significant.
GLOBALLY
- There are zero dual payload PDCs in clinical trials.
- There are Zero dual payload PDCs which have cleared IND studies
- Zero ATR inhibitors have been approved by the FDA
Avacta are preparing AVA6207 for IND enabling studies
Even the computer knows the context here.
'Avacta Therapeutics holds the most advanced publicly disclosed program with AVA6207, a third-generation pre|CISION® dual-payload PDC delivering a topoisomerase I inhibitor (TOP1i) and an ATR inhibitor (ATRi)'
What do you think happens to tumours when you take the most potent TOP1i in it's class Exatecan, (a drug pharma failed to harness for decades) and then add an ATR Inhibitor to stop DNA repair?
There are a long list of reasons Avacta will likely be the first company globally to have a dual payload PDC in clinical trials. The obvious one is that pharma have failed to harness Exatecan and its systemic toxicity. Avacta have cracked the safety and tolerability because of pre|CISION a delivery mechanism which pharma simply don't have.
The stage is set, the strategy in play....do pioneering things with assets pharma can't harness and make them pay big.
AVA6103 could be the largest revenue generating oncology drug when considering the total addressable market (TAM) potential of the 8 indications on the current trial. AVA6207 could be even more valuable and that is what is at stake here.
2 days and we learn which ATRI payload is being used and who the likely pharma owner of that asset is.
2+2=4 and has always been the case.
I lose zero sleep on your concerns personally.
I see it differently... 3rd party validation from Pharma is more important and changes everything and that will happen when AVCT are ready and trigger the late to the party 'specialists'.
The disclosure of the ATRI in the coming days could be a major pointer to what is coming very soon.
Regardless of your concerns AVCT continue to do pioneering things many cannot comprehend and perhaps that is also part of the issue....'cannot comprehend' what a team of 25 are delivering and the positive impacts it will have within an industry. It will go a long way to determining how next gen treatments are given and the outcomes that pre|CISION enables. The opportunity has NEVER been better.
It is comforting to know that despite 5 years in the clinic the pre|CISION science still has not been successfully challenged and that is because it is working. This is arguably the most crucial thing.
Totally agree. With a 60 day timeline for the FDA to review this can happen quickly.
An open question I have is what is planned for the JP Morgan Healthcare conference from the 12th Jan?
We are 61 days from that event and it's quite possible that in the 9 weeks since the 10th sept the data has matured enough to apply for Fast Track. Do the stars align time will tell.
@RAH00084 On the day of the best RNS in the company history we traded circa 5m shares. Today we have traded 4.6m and counting just getting up off the floor.
#AVCT releases the warheads which will make up AVA6207 next week.
The foundation of AVA6207 is AVA6103. Now proven in human.
Ownership of the ATR inhibitor, which will sit alongside Exatecan in AVA6207, will be highly informative.
Who owns the green payload AVCT seeks to use?
@RAH00084 Only 2-4 months until the wider market starts to perceive that #AVCT's AVA6103 could genuinely become a $20bn, $30bn, >$40bn per annum drug.
The best selling oncology drug in history.
That is, until the data for AVA6207 begin to emerge...!
#AVCT
Cohort 1
Began end of March
On 10 September, two patients remained on drug. That’s 5.5 months of disease stabilisation across stage 4 pancreatic cancer patients. Achieved with a 1.5mg dose of AVA6103.
I.e. their tumours are not seeing progression.
Cohort 2
Began ~mid May
On 10 September, five patients remained on drug. That’s ~4 months of disease stabilisation across stage 4 pancreatic/CRC/cervical cancer patients. Achieved with a 3mg dose of AVA6103.
I.e. their tumours are not seeing progression
Cohort 3
Began ~early July
On 10 September, (all) seven patients remained on drug. That’s ~2.5 months of disease stabilisation across stage 4 pancreatic/CRC/breast patients. Achieved with a 4.5mg dose of AVA6103
I.e. their tumours are not seeing progression
Cohort 4
Began began ~mid August
Dosing 6.8mg. Just below the Enhertu equivalent. Cohort 4 has completed enrolment as of 23 October.
Enrollment is ongoing in both arms of the study. 8 months into trial end of November.
It is quite clear AVA6103 is working. In human.
Funded well into May 2027. That’s ~7 months of funding after a 68p fundraise which saw the directors take £660k.
Cohort 5 (current cohort) projected to match the absolute dose of Enhertu.
Q2W scanned every 8 weeks.
Q3W scanned every 6 weeks.
Couple of biopsies up their sleeves. They know exactly what this drug is doing 7.5 months into trial.
The amount of ‘ hot takes’ I’ve read which are concerned about “funding into May when AVA6103 efficacy is not due to H1 2027” demonstrates enormous naivety.
For two reasons:
(1) the trial is flying, you’ll see efficacy early H1 2027 at this rate;
(2) the efficacy data (as a package) for AVA6103 is actually irrelevant for the assets AVCT is seeking to deal on: a 3rd party warhead; AVA6000; AVA6207.
Yes, the AVA6103 data supports the negotiations but they are not dealing on AVA6103.
Proving AVA6103 is working (to the extent the tech can transfer to a third party warhead) was done when they RNS’ed preCISION was proven.
Partners will receive this data under NDA on a constant basis.
Far more important are the commercials of those deals, which improve as the AVA6103 data grows.
That is to say the 6103 data *supports* the value discussion, rather than being the arbiter of any deal(s).
Crazy thought I know, but they have a strategy.
X3 separate deal avenues to deal on before May 2027.
Lots of noise. Little logic.
2/2
So in just a few short years Avacta have....
1. Removed cardio toxicity from Doxorubicin - A 50 year problem pharma failed to address.
2. The FDA removed the lifetime limit of AVA6000 which uses Doxorubicin as the warhead. This was the first time ever in a P1A trial a lifetime limit had been removed!
3. Then taken the most potent drug in its class Exatecan again one pharma could not harness at full strength and completely changed its safety and tolerability profile, its therapeutic index and half life.
4. Now takes Exatecan and pairs it with an ATRI inhibitor!!
The key differentiator here is 'Precision' the Avacta tumour targeting and delivery mechanism which just so happens to works on 90% of all solid tumours!!!!They have cracked the safety and tolerability limitations which is still a prolific problem for pharma. This enables them to target the tumour more successfully, deliver the payload to the tumour and see a significant reduction in typical toxicities.
Precision is checkmate for so much of the current industry thinking. Well done the AVCT a team of 20-25 people has done all that!!
#AVCT Advance further into pioneering oncology.....
A dual payload to be presented at EORTC in 2 weeks time. This is highly significant. A very high chance the second payload is pharma owned = Deal time.
There are only 3 dual payload ADC drugs in the clinic globally. Zero Dual PDCs which Avacta specialise in. First mover advantage in dual payload PDC's another first.
They really are at the tip of the spear here adding an ATRI inhibitor to inhibit resistance mechanisms. Pair that with Exatecan used in the AVA6103 trial and you you have a lethal cocktail pharma can only dream of before Avacta's arrival.
https://t.co/l5aiPAVw3l
1/2
Market is acting like #AVCT is funded into December 2026, rather than May 2027.
A lot can happen in a very short time in biotech.
And Avacta has x5 shots on goal:
AVA6000 (SGC)
AVA6000 (TNBC)
AVA6103 (multiple shots)
AVA6207 (also multiple shots)
PRECISION (to a 3rd party warhead)
Never been more confident - today buying Avacta is the cheapest and safest that it has ever been.
So I did !
@tom_the_bomb__@JStonker@Timj65 Roche had multiple failed FAP trials. I’m yet to hear about a positive one.
Avacta are 2 for 2 both in clinic still progressing as they cracked the FAP targeting and systemic toxicity issues!